SUBSCRIBE
SUBSCRIBE
News   Policy

CBER: Blood Grouping Reagent Anti-s (Monoclonal) (Seraclone) - Summary Basis for Regulatory Action

September 3, 2008 | 
1 min read

Approval Information: Blood Grouping Reagent Anti-s (Monoclonal) (Seraclone) - Summary Basis for Regulatory Action. Read more from the FDA.

Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Approvals
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome
December 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: 3D illustration of stem cells used for cell therapy
Cell therapy
Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD
December 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Businessman makes employee cuts as part of layoff
Layoffs
The 5 Largest Biopharma Layoffs of 2024
December 19, 2024
 · 
7 min read
 · 
Angela Gabriel
Facade of Novo Nordisk's office in Fremont, California
GLP-1
EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters
December 18, 2024
 · 
2 min read
 · 
Annalee Armstrong